← Back to Search

Gallium Ga 68-DOTATATE for Prostate Cancer

Phase 2

Waitlist Available

Led By Mehmet Asim Bilen, MD

Research Sponsored by Emory University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 year post-therapy

Awards & highlights

Study Summary

This trial studies how well gallium Ga 68-DOTATATE PET/CT works in treating patients with castration resistant prostate cancer that has spread to other places in the body.

Eligible Conditions

Castration-resistant Prostate Cancer
Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 year post-therapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 year post-therapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year post-therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Gallium Ga 68-DOTATATE uptake

Secondary outcome measures

Progression free survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Gallium Ga 68-DOTATATE PET/CTExperimental Treatment3 Interventions

Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CT (Computed Tomography)

2018

Completed Phase 2

~20

Gallium Ga 68-DOTATATE

2018

Completed Phase 2

~30

Positron Emission Tomography

2008

Completed Phase 2

~2240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor

1,638 Previous Clinical Trials

2,560,515 Total Patients Enrolled

17 Trials studying Prostate Cancer

7,157 Patients Enrolled for Prostate Cancer

Mehmet Asim Bilen, MDPrincipal InvestigatorEmory University

1 Previous Clinical Trials

19 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any risks associated with Gallium Ga 68-DOTATATE?

"Although Phase 2 trials have not yielded data supporting the efficacy of Gallium Ga 68-DOTATATE, there is enough evidence indicating its safety to merit a score of 2."

Answered by AI

Are we still able to sign patients up for this research project?

"This particular study is not searching for any more patients as of now. The trial was initially posted on February 22nd, 2018 and the most recent update occurred on March 3rd, 2022. There are 3773 other trials for prostate cancer and 18 different trials for Gallium Ga 68-DOTATATE that are still actively recruiting participants."

Answered by AI

Are there any other research studies that have used Gallium Ga 68-DOTATATE?

"There are 18 clinical trials underway researching Gallium Ga 68-DOTATATE. 0 of these research programs have advanced to Phase 3 testing. The primary location for these studies is Bethesda, Maryland; however, there are facilities in 51 different locations conducting research on Gallium Ga 68-DOTATATE."

Answered by AI

How many people are involved in this clinical trial?

"This particular trial is no longer active, however, there are 3773 other clinical trials related to prostate cancer and 18 studies for Gallium Ga 68-DOTATATE that are currently recruiting patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Mehmet Bilen 2018. "Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03448458.